1
|
Hifumi E, Ito Y, Tsujita M, Taguchi H, Uda T. Enzymatization of mouse monoclonal antibodies to the corresponding catalytic antibodies. Sci Rep 2024; 14:12184. [PMID: 38806597 PMCID: PMC11133420 DOI: 10.1038/s41598-024-63116-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Accepted: 05/24/2024] [Indexed: 05/30/2024] Open
Abstract
Catalytic antibodies possess a dual function that enables both antigen recognition and degradation. However, their time-consuming preparation is a significant drawback. This study developed a new method for quickly converting mice monoclonal antibodies into catalytic antibodies using site-directed mutagenesis. Three mice type monoclonal antibodies targeting hemagglutinin molecule of influenza A virus could be transformed into the catalytic antibodies by deleting Pro95 in CDR-3 of the light chain. No catalytic activity was observed for monoclonal antibodies and light chains. In contrast, the Pro95-deleted light chains exhibited a catalytic activity to cleave the antigenic peptide including the portion of conserved region of hemagglutinin molecule. The affinity of the Pro95-deleted light chains to the antigen increased approximately 100-fold compared to the wild-type light chains. In the mutants, three residues (Asp1, Ser92, and His93) come closer to the appropriate position to create the catalytic site and contributing to the enhancement of both catalytic function and immunoreactivity. Notably, the Pro95-deleted catalytic light chains could suppress influenza virus infection in vitro assay, whereas the parent antibody and the light chain did not. This strategy offers a rapid and efficient way to create catalytic antibodies from existing antibodies, accelerating the development for various applications in diagnostic and therapeutic applications.
Collapse
Affiliation(s)
- Emi Hifumi
- Institute for Research Management, Oita University, 700 Dannoharu, Oita-shi, Oita, 870-1192, Japan.
- Research Center for GLOBAL/LOCAL Infectious Diseases, Oita University, 700 Dannoharu, Oita-shi, Oita, 870-1192, Japan.
| | - Yuina Ito
- Institute for Research Management, Oita University, 700 Dannoharu, Oita-shi, Oita, 870-1192, Japan
- Graduate School of Engineering, Oita University, 700 Dannoharu, Oita-shi, Oita, 870-1192, Japan
| | - Moe Tsujita
- Institute for Research Management, Oita University, 700 Dannoharu, Oita-shi, Oita, 870-1192, Japan
- Graduate School of Engineering, Oita University, 700 Dannoharu, Oita-shi, Oita, 870-1192, Japan
| | - Hiroaki Taguchi
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagaki-cho, Suzuka, 510-0293, Japan
| | - Taizo Uda
- Institute for Research Management, Oita University, 700 Dannoharu, Oita-shi, Oita, 870-1192, Japan
- Materials Open Laboratory, Institute of Systems, Information Technologies and Nanotechnologies (ISIT), Fukuoka, 819-0388, Japan
| |
Collapse
|
2
|
Timofeeva AM, Shayakhmetova LS, Nikitin AO, Sedykh TA, Matveev AL, Shanshin DV, Volosnikova EA, Merkuleva IA, Shcherbakov DN, Tikunova NV, Sedykh SE, Nevinsky GA. Natural Antibodies Produced in Vaccinated Patients and COVID-19 Convalescents Hydrolyze Recombinant RBD and Nucleocapsid (N) Proteins. Biomedicines 2024; 12:1007. [PMID: 38790969 PMCID: PMC11118737 DOI: 10.3390/biomedicines12051007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2024] [Revised: 04/30/2024] [Accepted: 04/30/2024] [Indexed: 05/26/2024] Open
Abstract
Antibodies are protein molecules whose primary function is to recognize antigens. However, recent studies have demonstrated their ability to hydrolyze specific substrates, such as proteins, oligopeptides, and nucleic acids. In 2023, two separate teams of researchers demonstrated the proteolytic activity of natural plasma antibodies from COVID-19 convalescents. These antibodies were found to hydrolyze the S-protein and corresponding oligopeptides. Our study shows that for antibodies with affinity to recombinant structural proteins of the SARS-CoV-2: S-protein, its fragment RBD and N-protein can only hydrolyze the corresponding protein substrates and are not cross-reactive. By using strict criteria, we have confirmed that this proteolytic activity is an intrinsic property of antibodies and is not caused by impurities co-eluting with them. This discovery suggests that natural proteolytic antibodies that hydrolyze proteins of the SARS-CoV-2 virus may have a positive impact on disease pathogenesis. It is also possible for these antibodies to work in combination with other antibodies that bind specific epitopes to enhance the process of virus neutralization.
Collapse
Affiliation(s)
- Anna M. Timofeeva
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia (S.E.S.)
- Advanced Engineering School, Novosibirsk State University, 630090 Novosibirsk, Russia
| | | | - Artem O. Nikitin
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia (S.E.S.)
- Advanced Engineering School, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Tatyana A. Sedykh
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia (S.E.S.)
| | - Andrey L. Matveev
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia (S.E.S.)
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology Vector, 630559 Koltsovo, Russia (D.N.S.)
| | | | - Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology Vector, 630559 Koltsovo, Russia (D.N.S.)
| | - Dmitriy N. Shcherbakov
- State Research Center of Virology and Biotechnology Vector, 630559 Koltsovo, Russia (D.N.S.)
- Department of Physical-Chemistry, Biology and Biotechnology, Altay State University, 656049 Barnaul, Russia
| | - Nina V. Tikunova
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia (S.E.S.)
- Advanced Engineering School, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Sergey E. Sedykh
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia (S.E.S.)
- Advanced Engineering School, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Georgy A. Nevinsky
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia (S.E.S.)
- Advanced Engineering School, Novosibirsk State University, 630090 Novosibirsk, Russia
| |
Collapse
|
3
|
Catalytic Antibodies: Design, Expression, and Their Applications in Medicine. Appl Biochem Biotechnol 2023; 195:1514-1540. [PMID: 36222989 PMCID: PMC9554387 DOI: 10.1007/s12010-022-04183-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/28/2022] [Indexed: 01/24/2023]
Abstract
Catalytic antibodies made it feasible to develop new catalysts, which had previously been the subject of research. Scientists have discovered natural antibodies that can hydrolyze substrates such as nucleic acids, proteins, and polysaccharides during decades of research, as well as several ways of producing antibodies with specialized characteristics and catalytic functions. These antibodies are widely used in chemistry, biology, and medicine. Catalytic antibodies can continue to play a role and even fully prevent the emergence of autoimmune disorders, especially in the field of infection and immunity, where the process of its occurrence and development often takes a long time. In this work, the development, design and evolution methodologies, and the expression systems and applications of catalytic antibodies, are discussed. Trial registration: not applicable.
Collapse
|
4
|
Obtaining Highly Active Catalytic Antibodies Capable of Enzymatically Cleaving Antigens. Int J Mol Sci 2022; 23:ijms232214351. [PMID: 36430828 PMCID: PMC9697424 DOI: 10.3390/ijms232214351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 11/15/2022] [Accepted: 11/16/2022] [Indexed: 11/22/2022] Open
Abstract
A catalytic antibody has multiple functions compared with a monoclonal antibody because it possesses unique features to digest antigens enzymatically. Therefore, many catalytic antibodies, including their subunits, have been produced since 1989. The catalytic activities often depend on the preparation methods and conditions. In order to elicit the high catalytic activity of the antibodies, the most preferable methods and conditions, which can be generally applicable, must be explored. Based on this view, systematic experiments using two catalytic antibody light chains, #7TR and H34, were performed by varying the purification methods, pH, and chemical reagents. The experimental results obtained by peptidase activity tests and kinetic analysis, revealed that the light chain's high catalytic activity was observed when it was prepared under a basic condition. These data imply that a small structural modulation of the catalytic antibody occurs during the purification process to increase the catalytic activity while the antigen recognition ability is kept constant. The presence of NaCl enhanced the catalytic activity. When the catalytic light chain was prepared with these preferable conditions, #7TR and H34 hugely enhanced the degradation ability of Amyloid-beta and PD-1 peptide, respectively.
Collapse
|
5
|
A new catalytic site functioning in antigen cleavage by H34 catalytic antibody light chain. Sci Rep 2022; 12:19185. [PMID: 36357546 PMCID: PMC9649737 DOI: 10.1038/s41598-022-23689-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 11/03/2022] [Indexed: 11/12/2022] Open
Abstract
The cleavage reactions of catalytic antibodies are mediated by a serine protease mechanism involving a catalytic triad composed of His, Ser, and Asp residues, which reside in the variable region. Recently, we discovered a catalytic antibody, H34 wild type (H34wt), that is capable of enzymatically cleaving an immune-check point PD-1 peptide and recombinant PD-1; however, H34wt does not contain His residues in the variable region. To clarify the reason behind the catalytic features of H34wt and the amino acid residues involved in the catalytic reaction, we performed site-directed mutagenesis focusing on the amino acid residues involved in the cleavage reaction, followed by catalytic activity tests, immunological reactivity evaluation, and molecular modeling. The results revealed that the cleavage reaction by H34wt proceeds through the action of a new catalytic site composed of Arg, Thr, and Gln. This new scheme differs from that of the serine protease mechanism of catalytic antibodies.
Collapse
|
6
|
Hifumi E, Taguchi H, Nonaka T, Harada T, Uda T. Finding and characterizing a catalytic antibody light chain, H34, capable of degrading the PD-1 molecule. RSC Chem Biol 2021; 2:220-229. [PMID: 34458785 PMCID: PMC8341958 DOI: 10.1039/d0cb00155d] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Accepted: 11/11/2020] [Indexed: 11/25/2022] Open
Abstract
Programmed cell death 1 (PD-1) is an immune checkpoint molecule regulating T-cell function. Preventing PD-1 binding to its ligand PD-L1 has emerged as an important tool in immunotherapy. Here, we describe a unique human catalytic antibody light chain, H34, which mediates enzymatic degradation of human PD-1 peptides and recombinant human PD-1 protein and thus functions to prevent the binding of PD-1 with PD-L1. H34 degraded one half of the PD-1 molecules within about 6 h under the experimental conditions. Investigating the acquisition of the catalytic function by H34, which belongs to subgroup I and lacks a Pro95 residue in CDR-3, revealed the importance of this sequence, as a Pro95-reconstituted mutant (H34-Pro95(+)) exhibited very little catalytic activity to cleave PD-1. Interestingly, EDTA inhibited the catalytic activity of H34, which could work as a metallo-protease. Zn2+ or Co2+ ions may work as a cofactor. It is meaningfull that H34 was obtained from the human antibody gene taken from a healthy volunteer, suggesting that we potentially have such unique molecules in our body.
Collapse
Affiliation(s)
- Emi Hifumi
- Oita University, Research Promotion Institute 700 Dannoharu Oita-shi Oita 870-1192 Japan
| | - Hiroaki Taguchi
- Suzuka University of Medical Science, Faculty of Pharmaceutical Sciences 3500-3 Minamitamagaki-cho Suzuka 510-0293 Japan
| | - Tamami Nonaka
- Oita University, Research Promotion Institute 700 Dannoharu Oita-shi Oita 870-1192 Japan
| | - Takunori Harada
- Oita University, Faculty of Science & Technology, Division of Applied Chemistry 700 Dannoharu Oita-shi Oita 870-1192 Japan
| | - Taizo Uda
- Nanotechnology Laboratory, Institute of Systems, Information Technologies and Nanotechnologies (ISIT) 4-1 Kyudai-shinmachi Fukuoka 879-5593 Japan
| |
Collapse
|
7
|
Hifumi E, Taguchi H, Tsuda H, Minagawa T, Nonaka T, Uda T. A new algorithm to convert a normal antibody into the corresponding catalytic antibody. SCIENCE ADVANCES 2020; 6:eaay6441. [PMID: 32232151 PMCID: PMC7096177 DOI: 10.1126/sciadv.aay6441] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Accepted: 12/31/2019] [Indexed: 06/10/2023]
Abstract
Over thousands of monoclonal antibodies (mAbs) have been produced so far, and it would be valuable if these mAbs could be directly converted into catalytic antibodies. We have designed a system to realize the above concept by deleting Pro95, a highly conserved residue in CDR-3 of the antibody light chain. The deletion of Pro95 is a key contributor to catalytic function of the light chain. The S35 and S38 light chains have identical amino acid sequences except for Pro95. The former, with Pro95 did not show any catalytic activity, whereas the latter, without Pro95, exhibited peptidase activity. To verify the generality of this finding, we tested another light chain, T99wt, which had Pro95 and showed little catalytic activity. In contrast, a Pro95-deleted mutant enzymatically degraded the peptide substrate and amyloid-beta molecule. These two cases demonstrate the potential for a new method of creating catalytic antibodies from the corresponding mAbs.
Collapse
Affiliation(s)
- Emi Hifumi
- Oita University, Research Promotion Institute, 700 Dannoharu, Oita-shi, Oita 870-1192, Japan
| | - Hiroaki Taguchi
- Suzuka University of Medical Science, Faculty of Pharmaceutical Sciences, 3500-3 Minamitamagaki-cho, Suzuka 510-0293, Japan
| | - Haruna Tsuda
- Oita University, Research Promotion Institute, 700 Dannoharu, Oita-shi, Oita 870-1192, Japan
- Oita University, Department of Applied Chemistry, Faculty of Engineering, 700 Dannoharu, Oita-shi, Oita 870-1192, Japan
| | - Tetsuro Minagawa
- Oita University, Research Promotion Institute, 700 Dannoharu, Oita-shi, Oita 870-1192, Japan
- Oita University, Department of Applied Chemistry, Faculty of Engineering, 700 Dannoharu, Oita-shi, Oita 870-1192, Japan
| | - Tamami Nonaka
- Oita University, Research Promotion Institute, 700 Dannoharu, Oita-shi, Oita 870-1192, Japan
| | - Taizo Uda
- Oita University, Research Promotion Institute, 700 Dannoharu, Oita-shi, Oita 870-1192, Japan
- Nanotechnology Laboratory, Institute of Systems, Information Technologies and Nanotechnologies (ISIT), 4-1 Kyudai-shinmachi, Fukuoka 879-5593, Japan
| |
Collapse
|
8
|
Emergence of antibodies endowed with proteolytic activity against High-mobility group box 1 protein (HMGB1) in patients surviving septic shock. Cell Immunol 2019; 347:104020. [PMID: 31767118 DOI: 10.1016/j.cellimm.2019.104020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 10/29/2019] [Accepted: 11/14/2019] [Indexed: 12/24/2022]
Abstract
High-mobility group box 1 (HMGB1) concentration in serum or plasma has been proposed as an important biological marker in various inflammation-related pathologies. We previously showed that low titer autoantibodies against HMGB1 could emerge during the course of sepsis. Importantly their presence was positively related with patients' survival. In this study, we focused on plasma samples from 2 patients who survived sepsis and exhibited high titer antibodies to HMGB1. These antibodies were proved to be specific for HMGB1 since they did not bind to HMGB2 or to human serum albumin. Following IgG purification, it has shown that both patients secreted HMGB1-hydrolyzing autoantibodies in vitro. These findings suggested that proteolytic antibodies directed against HMGB1 can be produced in patients surviving septic shock.
Collapse
|
9
|
Hifumi E, Taguchi H, Toorisaka E, Uda T. New technologies to introduce a catalytic function into antibodies: A unique human catalytic antibody light chain showing degradation of β-amyloid molecule along with the peptidase activity. FASEB Bioadv 2019; 1:93-104. [PMID: 32123823 PMCID: PMC6996398 DOI: 10.1096/fba.1025] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Revised: 07/04/2018] [Accepted: 10/12/2018] [Indexed: 12/20/2022] Open
Abstract
Since the discovery of a natural catalytic antibody in 1989, many catalytic antibodies targeting peptides, nucleotides, virus and bacterial proteins, and many molecules have been prepared. Although catalytic antibodies should have features superior to non-catalytic monoclonal antibodies, the reports on catalytic antibodies are far fewer than those on normal (non-catalytic) antibodies. Nowadays, we can obtain any monoclonal antibody we want, which is not the case for catalytic antibodies. To overcome this drawback of catalytic antibodies, much basic research must be done. As one way to attain this purpose, we have been making a protein bank of human antibody light chains, in which the light chains were expressed, purified, and stored for use in screening against many kinds of antigen, to then get clues to introducing a catalytic function in normal antibodies. As the number of stored light chains in the above protein bank has reached the hundreds, in this study, we screened them against amyloid-beta (Aβ), which is well-known as one of the molecules causing Alzheimer's disease. We found two interesting light chains, #7TR and #7GY. The former could degrade both a fluorescence resonance energy transfer-Aβ substrate and Aβ1-40 full peptide. In contrast, #7GY, whose sequence is identical to that of #7TR except for the amino acids at the 29th and 30th positions, did not degrade the FRET-Aβ substrate at all. By using a synthetic substrate, Arg-pNA, the difference between the chemical features of the two light chains was investigated in detail. In addition, we found that the presence of Zn(II) ion hugely influenced the catalytic activity of the #7TR light chain but not #7GY. Through these facts and the discussion, we propose one of the clues to how to put a catalytic function in a normal (non-catalytic) antibody.
Collapse
Affiliation(s)
- Emi Hifumi
- Research Promotion Institute, Oita UniversityOitaJapan
| | - Hiroaki Taguchi
- Faculty of Pharmaceutical SciencesSuzuka University of Medical ScienceSuzukaJapan
| | - Eiichi Toorisaka
- Faculty of Engineering, Department of Sustainable EngineeringYamaguchi UniversityYamaguchiJapan
| | - Taizo Uda
- Faculty of Engineering, Department of Applied ChemistryOita UniversityOitaJapan
- Nanotechnology LaboratoryInstitute of Systems, Information Technologies and Nanotechnologies (ISIT)FukuokaJapan
| |
Collapse
|
10
|
Abstract
The existence of catalytic antibodies has been known for decades. Natural antibodies capable of cleaving nucleic acid, protein, and polysaccharide substrates have been described. Although the discovery of catalytic antibodies initially aroused great interest because of their promise for the development of new catalysts, their enzymatic performance has been disappointing due to low reaction rates. However, in the areas of infection and immunity, where processes often occur over much longer times and involve high antibody concentrations, even low catalytic rates have the potential to influence biological outcomes. In this regard, the presence of catalytic antibodies recognizing host antigens has been associated with several autoimmune diseases. Furthermore, naturally occurring catalytic antibodies to microbial determinants have been correlated with resistance to infection. Recently, there has been substantial interest in harnessing the power of antibody-mediated catalysis against microbial antigens for host defense. Additional work is needed, however, to better understand the prevalence, function, and structural basis of catalytic activity in antibodies. Here we review the available information and suggest that antibody-mediated catalysis is a fertile area for study with broad applications in infection and immunity.
Collapse
|
11
|
Hifumi E, Taguchi H, Kato R, Uda T. Role of the constant region domain in the structural diversity of human antibody light chains. FASEB J 2017; 31:1668-1677. [PMID: 28096233 DOI: 10.1096/fj.201600819r] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2016] [Accepted: 01/03/2017] [Indexed: 01/30/2023]
Abstract
Issues regarding the structural diversity (heterogeneity) of an antibody molecule have been the subject of discussion along with the development of antibody drugs. Research on heterogeneity has been extensive in recent years, but no clear solution has been reached. Heterogeneity is also observed in catalytic antibody κ light chains (CLs). In this study, we investigated how the constant region domain of CLs concerns structural diversity because it is a simple and good example for elucidating heterogeneity. By means of cation-exchange chromatography, SDS-PAGE, and 2-dimensional electrophoresis for the CL, multimolecular forms consisting of different electrical charges and molecular sizes coexisted in the solution, resulting in the similar heterogeneity of the full length of CLs. The addition of copper ion could cause the multimolecular forms to change to monomolecular forms. Copper ion contributed greatly to the enrichment of the dimer form of CL and the homogenization of the differently charged CLs. Two molecules of the CL protein bound one copper ion. The binding affinity of the ion was 48.0 μM-1 Several divalent metal ions were examined, but only zinc showed a similar effect.-Hifumi, E., Taguchi, H., Kato, R., Uda, T. Role of the constant region domain in the structural diversity of human antibody light chains.
Collapse
Affiliation(s)
- Emi Hifumi
- Research Promotion Institute, Oita University, Oita, Japan;
| | - Hiroaki Taguchi
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan
| | - Ryuichi Kato
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Japan
| | - Taizo Uda
- Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; and.,Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies, Fukuoka, Japan
| |
Collapse
|
12
|
Hifumi E, Matsumoto S, Nakashima H, Itonaga S, Arakawa M, Katayama Y, Kato R, Uda T. A novel method of preparing the monoform structure of catalytic antibody light chain. FASEB J 2015; 30:895-908. [PMID: 26527062 DOI: 10.1096/fj.15-276394] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 10/19/2015] [Indexed: 11/11/2022]
Abstract
Along with the development of antibody drugs and catalytic antibodies, the structural diversity (heterogeneity) of antibodies has been given attention. For >20 yr, detailed studies on the subject have not been conducted, because the phenomenon presents many difficult and complex problems. Structural diversity provides some (or many) isoforms of an antibody distinguished by different charges, different molecular sizes, and modifications of amino acid residues. For practical use, the antibody and the subunits must have a defined structure. In recent work, we have found that the copper (Cu) ion plays a substantial role in solving the diversity problem. In the current study, we used several catalytic antibody light chains to examine the effect of the Cu ion. In all cases, the different electrical charges of the molecule converged to a single charge, giving 1 peak in cation-exchange chromatography, as well as a single spot in 2-dimensional gel electrophoresis. The Cu-binding site was investigated by using mutagenesis, ultraviolet-visible spectroscopy, atomic force microscope analysis, and molecular modeling, which suggested that histidine and cysteine residues close to the C-terminus are involved with the binding site. The constant region domain of the antibody light chain played an important role in the heterogeneity of the light chain. Our findings may be a significant tool for preparing a single defined, not multiple, isoform structure.
Collapse
Affiliation(s)
- Emi Hifumi
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Shingo Matsumoto
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Hiroki Nakashima
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Shogo Itonaga
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Mitsue Arakawa
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Yoshiki Katayama
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Ryuichi Kato
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Taizo Uda
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| |
Collapse
|
13
|
Hifumi E, Arakawa M, Matsumoto S, Yamamoto T, Katayama Y, Uda T. Biochemical features and antiviral activity of a monomeric catalytic antibody light-chain 23D4 against influenza A virus. FASEB J 2015; 29:2347-58. [PMID: 25713031 DOI: 10.1096/fj.14-264275] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2014] [Accepted: 01/26/2015] [Indexed: 02/02/2023]
Abstract
Catalytic antibodies have exhibited interesting functions against some infectious viruses such as HIV, rabies virus, and influenza virus in vitro as well as in vivo. In some cases, a catalytic antibody light chain takes on several structures from the standpoint of molecular size (monomer, dimer, etc.) and/or isoelectronic point. In this study, we prepared a monomeric 23D4 light chain by mutating the C-terminal Cys to Ala of the wild-type. The mutated 23D4 molecule took a simple monomeric form, which could hydrolyze synthetic 4-methyl-coumaryl-7-amide substrates and a plasmid DNA. Because the monomeric 23D4 light chain suppressed the infection of influenza virus A/Hiroshima/37/2001 in an in vitro assay, the corresponding experiments were conducted in vivo, after the virus strain (which was taken from a human patient) was successfully adapted into BALB/cN Sea mice. In the experiments, a mixture of the monomeric 23D4 and the virus was nasally administered 1) with preincubation and 2) without preincubation. As a result, the monomeric 23D4 clearly exhibited the ability to suppress the influenza virus infection in both cases, indicating a potential drug for preventing infection of the influenza A virus.
Collapse
Affiliation(s)
- Emi Hifumi
- *Research Promotion Institute, Oita University, Oita-shi, Oita, Japan; Japan Science and Technology Agency-Core Research for Evolutional Science and Technology, Kawaguchi, Saitama, Japan; Faculty of Medicine, Oita University, Yufu-city, Oita, Japan; Department of Applied Chemistry; Oita University, Oita-shi, Oita, Japan; Graduate School of Systems Life Sciences, Kyushu University, Nishi-ku, Fukuoka, Japan; and Institute of Systems, Information Technologies and Nanotechnologies, Nanotechnology Laboratory, Fukuoka, Japan
| | - Mitsue Arakawa
- *Research Promotion Institute, Oita University, Oita-shi, Oita, Japan; Japan Science and Technology Agency-Core Research for Evolutional Science and Technology, Kawaguchi, Saitama, Japan; Faculty of Medicine, Oita University, Yufu-city, Oita, Japan; Department of Applied Chemistry; Oita University, Oita-shi, Oita, Japan; Graduate School of Systems Life Sciences, Kyushu University, Nishi-ku, Fukuoka, Japan; and Institute of Systems, Information Technologies and Nanotechnologies, Nanotechnology Laboratory, Fukuoka, Japan
| | - Shingo Matsumoto
- *Research Promotion Institute, Oita University, Oita-shi, Oita, Japan; Japan Science and Technology Agency-Core Research for Evolutional Science and Technology, Kawaguchi, Saitama, Japan; Faculty of Medicine, Oita University, Yufu-city, Oita, Japan; Department of Applied Chemistry; Oita University, Oita-shi, Oita, Japan; Graduate School of Systems Life Sciences, Kyushu University, Nishi-ku, Fukuoka, Japan; and Institute of Systems, Information Technologies and Nanotechnologies, Nanotechnology Laboratory, Fukuoka, Japan
| | - Tatsuhiro Yamamoto
- *Research Promotion Institute, Oita University, Oita-shi, Oita, Japan; Japan Science and Technology Agency-Core Research for Evolutional Science and Technology, Kawaguchi, Saitama, Japan; Faculty of Medicine, Oita University, Yufu-city, Oita, Japan; Department of Applied Chemistry; Oita University, Oita-shi, Oita, Japan; Graduate School of Systems Life Sciences, Kyushu University, Nishi-ku, Fukuoka, Japan; and Institute of Systems, Information Technologies and Nanotechnologies, Nanotechnology Laboratory, Fukuoka, Japan
| | - Yoshiki Katayama
- *Research Promotion Institute, Oita University, Oita-shi, Oita, Japan; Japan Science and Technology Agency-Core Research for Evolutional Science and Technology, Kawaguchi, Saitama, Japan; Faculty of Medicine, Oita University, Yufu-city, Oita, Japan; Department of Applied Chemistry; Oita University, Oita-shi, Oita, Japan; Graduate School of Systems Life Sciences, Kyushu University, Nishi-ku, Fukuoka, Japan; and Institute of Systems, Information Technologies and Nanotechnologies, Nanotechnology Laboratory, Fukuoka, Japan
| | - Taizo Uda
- *Research Promotion Institute, Oita University, Oita-shi, Oita, Japan; Japan Science and Technology Agency-Core Research for Evolutional Science and Technology, Kawaguchi, Saitama, Japan; Faculty of Medicine, Oita University, Yufu-city, Oita, Japan; Department of Applied Chemistry; Oita University, Oita-shi, Oita, Japan; Graduate School of Systems Life Sciences, Kyushu University, Nishi-ku, Fukuoka, Japan; and Institute of Systems, Information Technologies and Nanotechnologies, Nanotechnology Laboratory, Fukuoka, Japan
| |
Collapse
|
14
|
Hifumi E, Fujimoto N, Arakawa M, Saito E, Matsumoto S, Kobayashi N, Uda T. Biochemical features of a catalytic antibody light chain, 22F6, prepared from human lymphocytes. J Biol Chem 2013; 288:19558-68. [PMID: 23677996 PMCID: PMC3707657 DOI: 10.1074/jbc.m113.454579] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Human antibody light chains belonging to subgroup II of germ line genes were amplified by a seminested PCR technique using B-lymphocytes taken from a human adult infected with influenza virus. Each gene of the human light chains was transferred into the Escherichia coli system. The recovered light chain was highly purified using a two-step purification system. Light chain 22F6 showed interesting catalytic features. The light chain cleaved a peptide bond of synthetic peptidyl-4-methyl-coumaryl-7-amide (MCA) substrates, such as QAR-MCA and EAR-MCA, indicating amidase activity. It also hydrolyzed a phosphodiester bond of both DNA and RNA. From the analysis of amino acid sequences and molecular modeling, the 22F6 light chain possesses two kinds of active sites as amidase and nuclease in close distances. The 22F6 catalytic light chain could suppress the infection of influenza virus type A (H1N1) of Madin-Darby canine kidney cells in an in vitro assay. In addition, the catalytic light chain clearly inhibited the infection of the influenza virus of BALB/c mice via nasal administration in an in vivo assay. In the experiment, the titer in the serum of the mice coinfected with the 22F6 light chain and H1N1 virus became considerably lowered compared with that of 22F6-non-coinfected mice. Note that the catalytic light chain was prepared from human peripheral lymphocyte and plays an important role in preventing infection by influenza virus. Considering the fact that the human light chain did not show any acute toxicity for mice, our procedure developed in this study must be unique and noteworthy for developing new drugs.
Collapse
Affiliation(s)
- Emi Hifumi
- Research Center for Applied Medical Engineering, Oita University, Dan-noharu 700, Oita-shi, Oita 870-1192, Japan.
| | | | | | | | | | | | | |
Collapse
|
15
|
Mahendra A, Sharma M, Rao DN, Peyron I, Planchais C, Dimitrov JD, Kaveri SV, Lacroix-Desmazes S. Antibody-mediated catalysis: Induction and therapeutic relevance. Autoimmun Rev 2013. [DOI: 10.1016/j.autrev.2012.10.009] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
16
|
Belogurov A, Smirnov I, Ponomarenko N, Gabibov A. Antibody-antigen pair probed by combinatorial approach and rational design: bringing together structural insights, directed evolution, and novel functionality. FEBS Lett 2012; 586:2966-73. [PMID: 22841717 DOI: 10.1016/j.febslet.2012.07.046] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2012] [Revised: 07/18/2012] [Accepted: 07/18/2012] [Indexed: 10/28/2022]
Abstract
The unique hypervariability of the immunoglobulin (Ig) superfamily provides a means to create both binding and catalytic antibodies with almost any desired specificity and activity. The diversity of antigens and concept of adaptive response suggest that it is possible to find an antigen pair to any raised Ig. In the current review we discuss combinatorial approaches, which makes it possible to obtain an antibody with predefined properties, followed by 3D structure-based rational design to enhance or dramatically change its characteristics. A similar strategy, but applied to the second partner of the antibody-antigen pair, may result in selection of complementary substrates to the chosen Ig. Finally, 2D screening may be performed solving the "Chicken and Egg" problem when neither antibody nor antigen is known.
Collapse
Affiliation(s)
- Alexey Belogurov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | | | | | | |
Collapse
|
17
|
A novel molecular analysis of genes encoding catalytic antibodies. Mol Immunol 2012; 50:160-8. [PMID: 22325472 DOI: 10.1016/j.molimm.2012.01.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2011] [Revised: 01/09/2012] [Accepted: 01/12/2012] [Indexed: 10/14/2022]
Abstract
Among the numerous questions remaining opened about catalytic antibodies (abzymes), the understanding of the origin of the genes encoding them is of vital significance. An original statistical analysis of genes encoding abzymes is described in the present report. Results suggested that these genes display a high conservation degree with their germline counterpart and a limited number of amino acid changes. Hence, on the contrary with high-affinity antibodies, maturation process by accumulation of somatic hypermutations is not required for the catalytic function. We demonstrated that despite a weak somatic mutation rate, the physicochemical properties of mutated amino acid (AA) are predominantly dissimilar with that of the germline AA. Further, we developed a novel approach in order to analyze the nature of genes encoding catalytic antibodies. For the first time, an unexpected and significant high level expression of rare gene subgroups was noticed and emphasized. The data described in this paper would lay the foundation for future studies about origin of genes encoding catalytic antibodies.
Collapse
|
18
|
Hifumi E, Honjo E, Fujimoto N, Arakawa M, Nishizono A, Uda T. Highly efficient method of preparing human catalytic antibody light chains and their biological characteristics. FASEB J 2011; 26:1607-15. [PMID: 22205784 DOI: 10.1096/fj.11-195339] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The ultimate goal of catalytic antibody research is to develop new patient therapies that use the advantages offered by human catalytic antibodies. The establishment of a high-throughput method for obtaining valuable candidate catalytic antibodies must be accelerated to achieve this objective. In this study, based on our concept that we can find antibody light chains with a high probability of success if they include a serine protease-like catalytic triad composed of Ser, His, and Asp on a variable region of the antibody structure, we amplified and cloned DNAs encoding human antibody light chains from germline genes of subgroup II by seminested PCR using two primer sets designed for this purpose. Seven DNA fragments encoding light chains in 17 clones were derived from germline gene A18b, 6 DNA fragments from A3/A19, 2 DNA fragments from A17, and a clone DNA fragment from A5 and O11/O1. All light chains expressed in Escherichia coli and highly purified under nondenaturing conditions exhibited amidolytic activity against synthetic peptides. Some of the light chains exhibited unique features that suppressed the infectious activity of the rabies virus. Furthermore, the survival rate of mice in which a lethal level of the rabies virus was coinoculated directly into the brain with light chain 18 was significantly improved. In the case of humans, these results demonstrate that high-throughput selection of light chains possessing catalytic functions and specificity for a target molecule can be attained from a light-chain DNA library amplified from germline genes belonging to subgroup II.
Collapse
Affiliation(s)
- Emi Hifumi
- Research Center for Applied Medical Engineering, Faculty of Engineering, Oita University, 700 Dan-noharu, Oita-shi, Oita 870-1192, Japan
| | | | | | | | | | | |
Collapse
|
19
|
Hifumi E, Takao SI, Fujimoto N, Uda T. Catalytic and biochemical features of a monoclonal antibody heavy chain, JN1-2, raised against a synthetic peptide with a hemagglutinin molecule of influenza virus. J Am Chem Soc 2011; 133:15015-24. [PMID: 21861493 DOI: 10.1021/ja203922r] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
It has long been an important issue to produce a catalytic antibody that possesses the ability to lose the infectivity of a bacteria or virus. The monoclonal antibody JN1-2 was generated using a synthetic peptide (TGLRNGITNKVNSVIEKAA) conjugated with human IgG. The peptide sequence includes the conserved region of the hemagglutinin molecule (HA(1) and HA(2) domains), which locates on the envelope of the influenza virus and plays an important role in influenza A virus infection. The monoclonal antibody specifically reacted with the HA2 domain, not only of H2 but also of an H1 strain of the H1N1 subtype (H1 strain). The heavy chain (JN1-2-H) isolated from the parent antibody showed catalytic activity cleaving the above antigenic peptide with very high turnover (kcat = 26 min(-1)), and it could slowly degrade the recombinant HA(2) domain by the catalytic function. Interestingly, the heavy chain exhibited the ability to reduce the infectivity of type A H1N1 but not type B, indicating specificity to type A. This characteristic monoclonal catalytic antibody heavy chain could suppress the infection of the influenza virus in vitro assays.
Collapse
Affiliation(s)
- Emi Hifumi
- Research Center for Applied Medical Engineering, Oita University, Oita-shi, Oita, Japan
| | | | | | | |
Collapse
|
20
|
Zein HS, El-Sehemy AA, Fares MO, ElHefnawi M, Teixeira da Silva JA, Miyatake K. Generation, characterization, and docking studies of DNA-hydrolyzing recombinant Fab antibodies. J Mol Recognit 2011; 24:862-74. [DOI: 10.1002/jmr.1129] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
21
|
Hifumi E, Higashi K, Uda T. Catalytic digestion of human tumor necrosis factor-α by antibody heavy chain. FEBS J 2010; 277:3823-32. [PMID: 20718866 DOI: 10.1111/j.1742-4658.2010.07785.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
It has long been an important task to prepare a catalytic antibody capable of digesting a targeting crucial protein that controls specific life functions. Tumor necrosis factor-α (TNF-α) is a cytokine and an important molecule concerned with autoimmune diseases such as rheumatoid arthritis, chronic obstructive pulmonary disease, and Crohn's disease. A mAb (ETNF-6 mAb) raised against human TNF-α was prepared, and the steric conformation was created by using molecular modeling after the cDNA was sequenced. The heavy chain (ETNF-6-H) of the mAb was considered to possess a catalytic triad-like structure in the complementarity determining regions (CDRs). As a result, ETNF-6-H exhibited a peptidase and a protease activity. In fact, ETNF-6-H predominantly cleaved the Ser5-Arg6 bond of TNF-α at the first step, resulting in the generation of a fragment of ∼ 17 kDa. This fragment was digested to a smaller molecule of 15 kDa by scission of the Gln21-Ala22 bond. The intermediate product was further converted into a fragment of 13.3 kDa by successive cleavage of the Leu36-Leu37 and Asn39-Gly40 bonds. The heavy chain possessed a protease activity against TNF-α with a multicleavage site.
Collapse
Affiliation(s)
- Emi Hifumi
- Research Center for Applied Medical Engineering, Oita University, Oita, Japan
| | | | | |
Collapse
|
22
|
Molecular analysis of multicatalytic monoclonal antibodies. Mol Immunol 2010; 47:1747-56. [DOI: 10.1016/j.molimm.2010.02.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2010] [Accepted: 02/25/2010] [Indexed: 11/18/2022]
|
23
|
Hifumi E, Fujimoto N, Ishida K, Kawawaki H, Uda T. Characteristic features of InfA-15 monoclonal antibody recognizing H1, H3, and H5 subtypes of hemagglutinin of influenza virus A type. J Biosci Bioeng 2010; 109:598-608. [PMID: 20471600 DOI: 10.1016/j.jbiosc.2009.11.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2009] [Revised: 11/27/2009] [Accepted: 11/30/2009] [Indexed: 11/17/2022]
Abstract
Hemagglutinin molecule is an envelope protein of influenza virus and plays an important role in the infection to human cells. Many mutations are observed in the molecule, which generates sixteen subtypes (H1-H16) of the hemagglutinin molecule for influenza virus A type. The subtypes such as H1, H2, H3, and H5 out of the sixteen are underlined molecules, which are responsible to Spain, Asia, Hong Kong, and Avian Flu, respectively. Based on the sequence analysis, three short sequences, which are highly conserved in the subtypes of influenza virus A type, were extracted. The sequence peptides were chemically synthesized and conjugated with BSA for immunization into Balb/c mice. A sequence GMVDGWYG located at the domain of fusion protein in the hemagglutinin molecule exhibited a high immuno-response, resulting in the production of a monoclonal antibody (mAb; InfA-15). The unique features of InfA-15 mAb were investigated from the viewpoint of immunological reaction, the binding affinity, the steric conformation, etc. The InfA-15 mAb could react with the H1, H3, and H5 subtype of hemagglutinin molecule of influenza virus A type. ELISAs using InfA-15 mAb suggested a wide reaction spectrum for the hemagglutinin of many important influenza viruses A type.
Collapse
Affiliation(s)
- Emi Hifumi
- Research Center for Applied Medical Engineering, Oita University, 700 Dannoharu, Oita-shi, Oita 870-1192, Japan.
| | | | | | | | | |
Collapse
|
24
|
Structure-function analysis and molecular modeling of DNase catalytic antibodies. Immunol Lett 2010; 129:13-22. [PMID: 20097230 PMCID: PMC7112887 DOI: 10.1016/j.imlet.2010.01.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2009] [Revised: 12/26/2009] [Accepted: 01/14/2010] [Indexed: 11/22/2022]
Abstract
There is great interest in the antibodies-to-DNA transformation, since this change is characteristic of autoimmune diseases and contributes to its pathology. After immunization and fusions, 14 hybridomas bearing DNA-hydrolysis activity against pUC19 plasmid DNA were obtained. Genes coding for VH and VL regions of the 14 monoclonal antibodies (mAbs) were cloned and sequenced. The sequences were compared with sequences of the Ig-Blast database to determine their germline and to identify potential mutations responsible for DNA binding and DNase activity. V genes of the H chains’ genes expressed four genes of the VH1/J558 family, three of VH5/VH7183, and three of VH8/VH3609. The genetic repertoire of these mAbs was examined by determining the nucleotide sequences of their H chain V regions. This VH and VL domain was most similar to an anti-ssDNA (DNA-1) antibody as well as to catalytic autoimmune mAb (m3D8). Computer-generated models of the three-dimensional structures of VH and VL (VHL4) of the IgG4 combinations were used to define the positions occupied by the important sequence motifs at the binding sites. The modeling structure showed that VHL4 binds to oligo (dT3) primarily by sandwiching thymine bases between Tyr L32, Tyr L49 and Tyr H97 side-chains. Superposing VHL4 with anti-nucleic acid m3D8 catAbs revealed a common ssDNA recognition module consisting of His L93, His H35 residues which are critical for DNA-hydrolyzing antibodies. This study demonstrates the potential usefulness of the protein DNA surrogate in the investigation of the origin of anti-DNA antibodies’ hydrolyzing activities.
Collapse
|
25
|
Belogurov A, Kozyr A, Ponomarenko N, Gabibov A. Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde. Bioessays 2010; 31:1161-71. [PMID: 19795406 DOI: 10.1002/bies.200900020] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The immunoglobulin molecule is a perfect template for the de novo generation of biocatalytic functions. Catalytic antibodies, or abzymes, obtained by the structural mimicking of enzyme active sites have been shown to catalyze numerous chemical reactions. Natural enzyme analogs for some of these reactions have not yet been found or possibly do not exist at all. Nowadays, the dramatic breakthrough in antibody engineering and expression technologies has promoted a considerable expansion of immunoglobulin's medical applications and is offering abzymes a unique chance to become a promising source of high-precision "catalytic vaccines." At the same time, the discovery of natural abzymes on the background of autoimmune disease revealed their beneficial and pathogenic roles in the disease progression. Thus, the conflicting Dr. Jekyll and Mr. Hyde protective and destructive essences of catalytic antibodies should be carefully considered in the development of therapeutic abzyme applications.
Collapse
Affiliation(s)
- Alexey Belogurov
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117997, Russia
| | | | | | | |
Collapse
|
26
|
Sharma V, Heriot W, Trisler K, Smider V. A human germ line antibody light chain with hydrolytic properties associated with multimerization status. J Biol Chem 2009; 284:33079-87. [PMID: 19801545 DOI: 10.1074/jbc.m109.036087] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Antibodies with nucleophilic or catalytic properties often have these characteristics encoded in their germ line genes. Because hydrolytic activity has been reported to be associated with light chain V regions, we have begun an analysis of germ line light chain proteins that could be the basis for affinity maturation into hydrolytic or other reactive antibodies. We produced the germ line A18b light chain and characterized its hydrolytic, nucleophilic, and tertiary structural activities. This light chain was purified to >99% purity and found to hydrolyze aminomethylcoumarin-peptide and larger protein substrates and bind a fluorophosphonate probe. Mutation of putative catalytic residues only resulted in loss of activity of a tetrameric but not dimeric form of the light chain. These biochemical properties provide a framework for understanding the structure-function relationships of germ line antibodies.
Collapse
Affiliation(s)
- Vikram Sharma
- Integrigen, Incorporated, Novato, California 94949, USA
| | | | | | | |
Collapse
|
27
|
Parkhomenko TA, Odintsova ES, Buneva VN, Kunder EV, Zhyltsov IV, Senkovich SA, Generalov II, Nevinsky GA. DNA-hydrolysing activity of IgG antibodies from the sera of patients with diseases caused by different bacterial infections. J Cell Mol Med 2009; 13:2875-87. [PMID: 18671763 PMCID: PMC4498943 DOI: 10.1111/j.1582-4934.2008.00441.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2008] [Accepted: 06/10/2008] [Indexed: 12/02/2022] Open
Abstract
DNase autoantibodies (Abs) can be found in the blood of patients with several autoimmune diseases, while the blood of healthy donors or patients with diseases with insignificant disturbances of the immune status does not contain the DNase Abs. Here we have analysed for the first time the DNase activity in the patients with diseases caused by several bacterial infections. Several rigid criteria have been applied to show that the DNase activity is an intrinsic property of IgGs from the sera of patients with bacterial diseases but not from healthy donors. The relative activity of IgGs has been shown to vary extensively between the diseases analysed and from patient to patient, but most of the preparations had detectable levels of the DNase activity. On average, the catalytic activities were significantly lower than in patients with autoimmune pathologies and increased in the following order: streptococcal infection (erysipelas) < urogenital chlamydiosis associated with arthritis (Reiter's disease) < meningococcal meningitis < shigellosis < suppurative surgical infections caused by Staphylococcus aureus < suppurative surgical infections caused by epidermal staphylococci < urogenital ureaplasmosis associated with reactive arthritis. While intact IgGs possessed this catalytic activity, separated light chains of polyclonal Abs appeared to be even more active in the hydrolysis of DNA.
Collapse
Affiliation(s)
- Taisiya A Parkhomenko
- Institute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian DivisionNovosibirsk, Russia
| | - Elena S Odintsova
- Institute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian DivisionNovosibirsk, Russia
| | - Valentina N Buneva
- Institute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian DivisionNovosibirsk, Russia
- Novosibirsk State UniversityNovosibirsk, Russia
| | | | | | | | | | - Georgy A Nevinsky
- Institute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian DivisionNovosibirsk, Russia
- Novosibirsk State UniversityNovosibirsk, Russia
| |
Collapse
|
28
|
Zein HS, da Silva JAT, Miyatake K. Monoclonal antibodies specific to Cucumber mosaic virus coat protein possess DNA-hydrolyzing activity. Mol Immunol 2009; 46:1527-33. [PMID: 19187964 DOI: 10.1016/j.molimm.2008.12.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2007] [Revised: 12/21/2008] [Accepted: 12/24/2008] [Indexed: 11/21/2022]
Abstract
Monoclonal antibodies (mAbs) specific to Cucumber mosaic virus coat protein (CMV-CP) were designed from cDNA and deduced amino acid sequences of the light chain genes of 10 out of 14 different hybridoma cell lines. Ten of these mAbs revealed a very restricted germline family VkappaII, within which gene bd2 has identical amino acid sequences with VIPase and an i41SL 1-2 catalytic antibody light chain, both of which possess peptidase activity. Four out of the 14 mAbs illustrated another germline family VkappaIA, within which gene bb1.1 had high homology with BV04-01 light chain mAb, which hydrolyses ssDNA. Interestingly, our mAbs showed DNA-hydrolytic activity at an optimum pH of 4-5, which is a typical pattern of autoimmune diseases in which autoantibodies hydrolyze supercoiled plasmid DNA. This is the first evidence ever that CMV-CP could stimulate catalytic antibodies, which have an identical sequence homology with autoantibodies. Furthermore, the CMV-CP-specific mAbs will be important for isolating antibodies specific to the CPs of bacteria, viruses, cancer cells, etc. that could be used for medical therapy.
Collapse
Affiliation(s)
- Haggag S Zein
- Department of Genetics, Faculty of Agriculture, Cairo University, Giza 121613, Egypt.
| | | | | |
Collapse
|
29
|
Taguchi H, Planque S, Sapparapu G, Boivin S, Hara M, Nishiyama Y, Paul S. Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem 2008; 283:36724-33. [PMID: 18974093 DOI: 10.1074/jbc.m806766200] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Nucleophilic sites in the paired variable domains of the light and heavy chains (VL and VH domains) of Ig can catalyze peptide bond hydrolysis. Amyloid beta (Abeta)-binding Igs are under consideration for immunotherapy of Alzheimer disease. We searched for Abeta-hydrolyzing human IgV domains (IgVs) in a library containing a majority of single chain Fv clones mimicking physiological VL-VH-combining sites and minority IgV populations with nonphysiological structures generated by cloning errors. Random screening and covalent selection of phage-displayed IgVs with an electrophilic Abeta analog identified rare IgVs that hydrolyzed Abeta mainly at His14-Gln15. Inhibition of IgV catalysis and irreversible binding by an electrophilic hapten suggested a nucleophilic catalytic mechanism. Structural analysis indicated that the catalytic IgVs are nonphysiological structures, a two domain heterodimeric VL (IgVL2-t) and single domain VL clones with aberrant polypeptide tags (IgVL-t'). The IgVs hydrolyzed Abeta at rates superior to naturally occurring Igs by 3-4 orders of magnitude. Forced pairing of the single domain VL with VH or VL domains resulted in reduced Abeta hydrolysis, suggesting catalysis by the unpaired VL domain.Angstrom level amino acid displacements evident in molecular models of the two domain and unpaired VL domain clones explain alterations of catalytic activity. In view of their superior catalytic activity, the VL domain IgVs may help attain clearance of medically important antigens more efficiently than natural Igs.
Collapse
Affiliation(s)
- Hiroaki Taguchi
- Chemical Immunology Research Center, Department of Pathology and Laboratory Medicine, University of Texas Houston Medical School, Houston, Texas 77030, USA
| | | | | | | | | | | | | |
Collapse
|
30
|
Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, Friedland RP, Ramsland PA, Edmundson AB, Weksler ME, Paul S. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 2007; 283:4714-22. [PMID: 18086674 DOI: 10.1074/jbc.m707983200] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We describe IgM class human autoantibodies that hydrolyze amyloid beta peptide 1-40 (Abeta40). A monoclonal IgM from a patient with Waldenström's macroglobulinemia hydrolyzed Abeta40 at the Lys-28-Gly-29 bond and Lys-16-Ala-17 bonds. The catalytic activity was inhibited stoichiometrically by an electrophilic serine protease inhibitor. Treatment with the catalytic IgM blocked the aggregation and toxicity of Abeta40 in neuronal cell cultures. IgMs purified from the sera of patients with Alzheimer disease (AD) hydrolyzed Abeta40 at rates superior to IgMs from age-matched humans without dementia. IgMs from non-elderly humans expressed the least catalytic activity. The reaction rate was sufficient to afford appreciable degradation at physiological Abeta and IgM concentrations found in peripheral circulation. Increased Abeta concentrations in the AD brain are thought to induce neurodegenerative effects. Peripheral administration of Abeta binding antibodies has been suggested as a potential treatment of AD. Our results suggest that catalytic IgM autoantibodies can help clear Abeta, and they open the possibility of using catalytic Abs for AD immunotherapy.
Collapse
Affiliation(s)
- Hiroaki Taguchi
- Chemical Immunology Research Center, Department of Pathology and Laboratory Medicine, University of Texas Houston Medical School, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiyama Y, Kyle R, Okhuysen P, Escobar M, Hunter R, Sheppard HW, Hanson C, Paul S. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection. AIDS Res Hum Retroviruses 2007; 23:1541-54. [PMID: 18160012 DOI: 10.1089/aid.2007.0081] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Antibody hydrolysis of the superantigenic gp120 site and HIV-1 neutralization was studied as a potential anti-HIV mechanism in uninfected humans. gp120 hydrolysis by purified serum and salivary antibodies was determined by electrophoresis and peptide sequencing, the proteolytic mechanism was analyzed using electrophilic peptide analogs, and viral neutralization was studied using peripheral blood mononuclear cells as hosts. Polyclonal and monoclonal IgA but not IgG preparations selectively catalyzed the cleavage of HIV gp120 at rates sufficient to predict biologically relevant protection against the virus. The IgA hydrolytic reaction proceeded by noncovalent recognition of gp120 residues 421-433, a component of the superantigenic site of gp120, coordinated with peptide bond cleavage via a serine protease-like mechanism. The Lys-432-Ala-433 bond was one of the cleavage sites. Infection of peripheral blood mononuclear cells by a primary isolate of HIV was neutralized by the IgA but not IgG fractions. The neutralizing activity was specifically inhibited by an electrophilic inhibitor of the catalytic activity. The existence of catalytic IgAs to gp120 in uninfected humans suggests their role in resistance to HIV.
Collapse
Affiliation(s)
- Stephanie Planque
- Chemical Immunology Research Center, Departments of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas-Houston Medical School, Houston, Texas 77030
| | - Yukie Mitsuda
- Chemical Immunology Research Center, Departments of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas-Houston Medical School, Houston, Texas 77030
| | - Hiroaki Taguchi
- Chemical Immunology Research Center, Departments of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas-Houston Medical School, Houston, Texas 77030
| | - Maria Salas
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, California 94804
| | - Mary-Kate Morris
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, California 94804
| | - Yasuhiro Nishiyama
- Chemical Immunology Research Center, Departments of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas-Houston Medical School, Houston, Texas 77030
| | - Robert Kyle
- Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905
| | - Pablo Okhuysen
- Chemical Immunology Research Center, Departments of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas-Houston Medical School, Houston, Texas 77030
| | - Miguel Escobar
- Chemical Immunology Research Center, Departments of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas-Houston Medical School, Houston, Texas 77030
| | - Robert Hunter
- Chemical Immunology Research Center, Departments of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas-Houston Medical School, Houston, Texas 77030
| | - Haynes W. Sheppard
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, California 94804
| | - Carl Hanson
- Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, California 94804
| | - Sudhir Paul
- Chemical Immunology Research Center, Departments of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas-Houston Medical School, Houston, Texas 77030
| |
Collapse
|
32
|
Hifumi E, Morihara F, Hatiuchi K, Okuda T, Nishizono A, Uda T. Catalytic features and eradication ability of antibody light-chain UA15-L against Helicobacter pylori. J Biol Chem 2007; 283:899-907. [PMID: 17991752 DOI: 10.1074/jbc.m705674200] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We have successfully developed a catalytic antibody capable of degrading the active site of the urease of Helicobacter pylori and eradicating the bacterial infection in a mouse stomach. This monoclonal antibody UA15 was generated using a designed recombinant protein UreB, which contained the crucial region of the H. pylori urease beta-subunit active site, for immunization. The light chain of this antibody (UA15-L) by itself showed a proteolytic activity to substantially degrade both UreB and the intact urease. Oral administration of UA15-L also significantly reduced the number of H. pylori in a mouse stomach. This is the first example of a monoclonal catalytic antibody capable of functioning in vivo, and such an antibody may have a therapeutic utility in the future.
Collapse
Affiliation(s)
- Emi Hifumi
- Research Center for Applied Medical Engineering, Oita University, Dan-noharu 700, Oita-shi, Oita 870-1192, Japan
| | | | | | | | | | | |
Collapse
|
33
|
Okochi N, Kato-Murai M, Kadonosono T, Ueda M. Design of a serine protease-like catalytic triad on an antibody light chain displayed on the yeast cell surface. Appl Microbiol Biotechnol 2007; 77:597-603. [PMID: 17899065 DOI: 10.1007/s00253-007-1197-0] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2007] [Revised: 09/05/2007] [Accepted: 09/06/2007] [Indexed: 11/26/2022]
Abstract
Lc-WT, the wild-type light chain of antibody, and Lc-Triad, its double mutant with E1D and T27aS designing for the construction of catalytic triad within Asp1, Ser27a, and original His93 residues, were displayed on the cell surface of the protease-deficient yeast strain BJ2168. When each cell suspension was reacted with BODIPY FL casein and seven kinds of peptide-MCA substrates, respectively, a remarkable difference in hydrolytic activities toward Suc-GPLGP-MCA (succinyl-Gly-Pro-Leu-Gly-Pro-MCA), a substrate toward collagenase-like peptidase, was observed between the constructs: Lc-Triad-displaying cells showed higher catalytic activity than Lc-WT-displaying cells. The difference disappeared in the presence of the serine protease inhibitor diisopropylfluorophosphate, suggesting that the three amino acid residues, Ser27a, His93, and Asp1, functioned as a catalytic triad responsible for the proteolytic activity in a similar way to the anti-vasoactive intestinal peptide (VIP) antibody light chain. A serine protease-like catalytic triad (Ser, His, and Asp) is considered to be directly involved in the catalytic mechanism of the anti-VIP antibody light chain, which moderately catalyzes the hydrolysis of VIP. These results suggest the possibility of new approach for the creation of tailor-made proteases beyond limitations of the traditional immunization approach.
Collapse
Affiliation(s)
- Norihiko Okochi
- Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa Oiwake-cho, Sakyo-ku, Kyoto, 606-8502, Japan
| | | | | | | |
Collapse
|
34
|
Ponomarenko NA, Vorobiev II, Alexandrova ES, Reshetnyak AV, Telegin GB, Khaidukov SV, Avalle B, Karavanov A, Morse HC, Thomas D, Friboulet A, Gabibov AG. Induction of a protein-targeted catalytic response in autoimmune prone mice: antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry 2006; 45:324-30. [PMID: 16388609 DOI: 10.1021/bi050675k] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
We have induced a polyclonal IgG that degrades the HIV-1 surface antigen, glycoprotein gp120, by taking advantage of the susceptibility of SJL mice to a peptide-induced autoimmune disorder, experimental autoimmune encephalomyelitis (EAE). Specific pathogen-free SJL mice were immunized with structural fragments of gp120, fused in-frame with encephalitogenic peptide MBP(85-101). It has resulted in a pronounced disease-associated immune response against antigens. A dramatic increase of gp120 degradation level by purified polyclonal IgG from immunized versus nonimmunized mice has been demonstrated by a newly developed fluorescence-based assay. This activity was inhibited by anti-mouse immunoglobulin antibodies as well as by Ser- and His-reactive covalent inhibitors. A dominant proteolysis site in recombinant gp120 incubated with purified polyclonal IgG from immunized mice was shown by SDS-PAGE. The SELDI-based mass spectrometry revealed that these antibodies exhibited significant specificity toward the Pro484-Leu485 peptide bond. The sequence surrounding this site is present in nearly half of the HIV-I variants. This novel strategy can be generalized for creating a catalytic vaccine against viral pathogens.
Collapse
Affiliation(s)
- Natalia A Ponomarenko
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, RAS, 16/10, Miklukho-Maklaya str., Moscow 117871, Russia
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Paul S, Nishiyama Y, Planque S, Taguchi H. Theory of proteolytic antibody occurrence. Immunol Lett 2006; 103:8-16. [PMID: 16290203 DOI: 10.1016/j.imlet.2005.10.003] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2005] [Revised: 10/09/2005] [Accepted: 10/09/2005] [Indexed: 11/22/2022]
Abstract
Antibodies (Abs) with proteolytic and other catalytic activities have been characterized in the blood and mucosal secretions of humans and experimental animals. The catalytic activity can be traced to nucleophilic sites of innate origin located in Ab germline variable regions. Discoveries of the natural chemical reactivity of Abs were initially met with bewilderment, as the notion had taken hold that catalytic activities can be introduced into Abs by artificial means, but somatically operative selection pressures are designed only to adapt non-covalent Ab binding to antigen ground states. Unsurprisingly, initial efforts to engineer Abs with catalytic activity were oriented towards improving the non-covalent binding at the atoms immediately within the transition state reaction center. Slowly, however, dogmatic approaches to Ab catalysis have given way to the realization that efficient and specific catalytic Abs can be prepared by improving the natural nucleophilic reactivity combined with non-covalent recognition of epitope regions remote from the reaction center. The field remains beset, however, with controversy. This article attempts to provide a rational basis for natural Ab catalysis, in the hope that understanding this phenomenon will stimulate medical and basic science advances in the field.
Collapse
Affiliation(s)
- Sudhir Paul
- Chemical Immunology and Therapeutics Research Center, Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, 6431 Fannin, 77030, USA.
| | | | | | | |
Collapse
|
36
|
Hifumi E, Yamada Y, Uda T. A catalytic antibody heavy chain HpU-2 degrading its epitope peptide and H. pylori urease. Immunol Lett 2006; 103:68-74. [PMID: 16321448 DOI: 10.1016/j.imlet.2005.10.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2005] [Accepted: 10/14/2005] [Indexed: 11/15/2022]
Abstract
The HpU-2 monoclonal antibody (mAb) raised against Helicobacter pylori urease mainly recognized the alpha-subunit of the urease. On the other hand, the heavy chain of HpU-2 mAb (HpU-2-H) isolated from the parent mAb recognized both the alpha- and beta-subunit, in which the beta-subunit was recognized more strongly than the beta-subunit. HpU-2-H cleaved a peptide, SVELIDIGGNRRIFGFNALVD, which is the epitope sequence recognized by HpU-2 mAb, showing a double-phase reaction profile at 25 degrees C in a phosphate buffer. After an induction time of 24h, the cleavage of the peptide was initiated by HpU-2-H at a high rate and it was completed at 80 h of incubation. By mass spectroscopy, two main fragmented peptides, SVELIDIGGNRR and SVELIDIGGNRRIFG, were identified. In addition, many small peptide fragments were produced by successive cleavage of the fragmented peptides. Cleavage tests for H. pylori urease by HpU-2-H revealed that the beta-subunit of the urease was cleaved first and completely decomposed at 20 h of incubation. Cleavage of the alpha-subunit started after the complete decomposition of the beta-subunit. These cleavage results were in good agreement with the immunological features of HpU-2-H. The irrelevant proteins, BSA and HSA, were hardly cleaved by HpU-2-H.
Collapse
Affiliation(s)
- Emi Hifumi
- Faculty of Life and Enviromental Science, Prefectural University of Hiroshima, Shobara 727-0023, Japan
| | | | | |
Collapse
|
37
|
Dimmock NJ. The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis. Rev Med Virol 2005; 15:365-81. [PMID: 16106492 DOI: 10.1002/rmv.476] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The newly discovered external tail loop within the C-terminal tail of the gp41 transmembrane subunit of the HIV-1 envelope protein comprises approximately 40 residues, and within this are 18-residues ((734)PDRPEGIEEEGGERDRDR(751)) that include three antibody-reactive regions. The antigenicity is complex, and changes according to the biological context of the gp41. It is thus of interest both to the HIV specialist and protein immunologists. The antibody-reactive region, centred on the sequence ERDRD, encompasses three distinct epitopes which are expressed in different combinations on infected cells, wt virions, prefusion virion-cell complexes, and a neutralising antibody escape mutant virion. In addition ERDRD-specific antibodies have one or more antiviral activities, and variously neutralise the infectivity of free virions, neutralise virions already attached to the target cell, reduce the production of infectious progeny, and inhibit the ability of infected cells to fuse with non-infected cells. Antibodies to PDRPEG and IEEE have no apparent antiviral activity even though the footprints of the IEEE- and ERDRD-specific antibodies overlap. This review marshals the available experimental data with the aim of understanding the significance of the gp41 tail loop to the HIV-1 life cycle, and its relevance to potential anti-viral measures. There are lessons here, too, that are relevant to the comprehension of the antigenicity of short protein segments in general.
Collapse
Affiliation(s)
- Nigel J Dimmock
- Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK.
| |
Collapse
|
38
|
Uda T, Hifumi E. Super catalytic antibody and antigenase. J Biosci Bioeng 2005; 97:143-52. [PMID: 16233607 DOI: 10.1016/s1389-1723(04)70183-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2003] [Accepted: 12/02/2003] [Indexed: 11/21/2022]
Abstract
By immunizing ground-state peptides or proteins, we can produce super catalytic antibodies possessing serine protease-like characteristics. The unique feature of super catalytic antibodies is their ability to decompose a target molecule that is being killed. The authors have succeeded in preparing super catalytic antibodies that destroy (i) the HIV-1 envelope protein gp41, (ii) chemokine receptor CCR5 peptide, and (iii) Helicobacter pylori urease, etc. Some of them can degrade antigens at high catalytic reaction rates. Regarding their Km and kcat, super catalytic antibodies show intermediary values between that of enzymes (high Km and kcat) and that of antibodies (low Km and kcat [=0]). The catalytic function of an antibody mostly resides in its light chain. From mouse Vkappa germline analysis, it became clear that super catalytic antibodies are generated from some discrete germlines such as bb1, cr1, cs1, bl1, bj2 and bd2. In these Vkappa germlines, at least one catalytic triad composed of three amino acid residues, namely, Asp1, Ser27a and His93, is encoded. Namely, the antibody light chains (super catalytic antibodies) generated from the germlines are inherently able to enzymatically decompose antigens. Thus, such antibody light chains can be referred to as antigenase (antigen-decomposing enzyme) and may have arisen during the evolution of antibodies to acquire a higher ability than that of enzymes for developing a sophisticated self-defense system for survival.
Collapse
Affiliation(s)
- Taizo Uda
- School of Biosciences, Hiroshima Prefectural University, 562 Nanatsuka, Shoubara City, Hiroshima 727-0023, Japan.
| | | |
Collapse
|
39
|
Hifumi E, Hatiuchi K, Okuda T, Nishizono A, Okamura Y, Uda T. Specific degradation of H. pylori urease by a catalytic antibody light chain. FEBS J 2005; 272:4497-505. [PMID: 16128818 DOI: 10.1111/j.1742-4658.2005.04869.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Catalytic antibodies capable of digesting crucial proteins of pathogenic bacteria have long been sought for potential therapeutic use. Helicobacter pylori urease plays a crucial role for the survival of this bacterium in the highly acidic conditions of human stomach. The HpU-9 monoclonal antibody (mAb) raised against H. pylori urease recognized the alpha-subunit of the urease, but only slightly recognized the beta-subunit. However, when isolated both the light and the heavy chains of this antibody were mostly bound to the beta-subunit. The cleavage reaction catalyzed by HpU-9 light chain (HpU-9-L) followed the Michaelis-Menten equation with a K(m) of 1.6 x 10(-5) m and a k(cat) of 0.11 min(-1), suggesting that the cleavage reaction was enzymatic. In a cleavage test using H. pylori urease, HpU-9-L efficiently cleaved the beta-subunit but not the alpha-subunit, indicating that the degradation by HpU-9-L had a specificity. The cleaved peptide bonds in the beta-subunit were L121-A122, E124-G125, S229-A230, Y241-D242, and M262-A263. BSA was hardly cleaved by HpU-9-L, again indicating the digestion by HpU-9-L was specific. In summary, we succeeded in the preparation of a catalytic antibody light chain capable of specifically digesting the beta-subunit of H. pylori urease.
Collapse
Affiliation(s)
- Emi Hifumi
- Prefectural University of Hiroshima, Faculty of Bioscience and Environment, Hiroshima, Japan
| | | | | | | | | | | |
Collapse
|
40
|
Mitsuda Y, Tsuruhata K, Hifumi E, Takagi M, Uda T. Investigation of active form of catalytic antibody light chain 41S-2-L. Immunol Lett 2005; 96:63-71. [PMID: 15585309 DOI: 10.1016/j.imlet.2004.07.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2004] [Revised: 07/21/2004] [Accepted: 07/29/2004] [Indexed: 11/20/2022]
Abstract
We have raised a monoclonal antibody (41S-2) against the conserved sequence, RGPDRPEGIEEEGGERDRD, of human immunodeficiency virus type1 (HIV-1) envelope gp41. That antibody light chain (41S-2-L) cleaves gp41-derived peptide (TPRGPDRPEGIEEEGGERDRD; TP41-1) with a characteristic biphasic profile composed of induction and active phases. It is considered that the conformation of 41S-2-L is changed, by such as induced fitting, to move to active phase to decompose the antigenic peptide during the induction phase. In order to investigate what happens to 41S-2-L in the induction and active phase, the cleavage reaction of the peptide by 41S-2-L was examined in detail from the viewpoint of kinetic and spectroscopic analysis. The kinetic data showed that the preferable conformational transition of 41S-2-L took place by the unimolecular reaction of 41S-2-L in the induction phase. UV-vis and fluorescence spectroscopic analysis suggested that the conformational transition leads to the generation of aggregates of 41S-2-L in the reacting solution, which causes the huge enhancement of the catalytic activity of 41S-2-L. The nuclei of the aggregates may be formed in the induction phase. The aggregates and soluble 41S-2-L are considered to be in chemical equilibrium during the cleavage reaction of the antigen.
Collapse
Affiliation(s)
- Yukie Mitsuda
- School of Biosciences, Hiroshima Prefectural University, 562 Nanatsuka, Shobara City, Hiroshima 727-0023, Japan
| | | | | | | | | |
Collapse
|
41
|
Mitsuda Y, Hifumi E, Tsuruhata K, Fujinami H, Yamamoto N, Uda T. Catalytic antibody light chain capable of cleaving a chemokine receptor CCR-5 peptide with a high reaction rate constant. Biotechnol Bioeng 2004; 86:217-25. [PMID: 15052642 DOI: 10.1002/bit.20031] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
A monoclonal antibody (MAb), ECL2B-2, was obtained by immunizing a peptide possessing a part of a sequence of a chemokine receptor, CCR-5, which is present as a membrane protein on the macrophage surface, and which plays an important role in human immunodeficiency virus (HIV) infection. From the DNA and the deduced amino acid sequences of the light and heavy chains of ECL2B-2 MAb, molecular modeling was conducted to calculate the steric conformation of the antibody. Modeling suggested that the structure of ECL2B-2 could possess one or two catalytic triad(s), composed of Asp(1), Ser(27a) (or Ser(27e)), and His(93) (or His(27d)), in the light chain of ECL2B-2. The three amino acid residues, Asp(1), Ser(27a), and His(93), are identical to those of catalytic antibody light chains such as VIPase and i41SL1-2. The light chain of ECL2B-2 MAb degraded the antigenic peptide CCR-5 within about 100 h. Surprisingly, the light chain had a very high catalytic reaction rate constant (k(cat)) of 2.23 min(-1), which is greater by factors of tens to hundreds than those of natural catalytic antibodies obtained previously. The heavy chain of ECL2B-2 MAb, which has no catalytic triad because of a lack of His residue, did not degrade the CCR-5 peptide.
Collapse
Affiliation(s)
- Yukie Mitsuda
- School of Biosciences, Hiroshima Prefectural University, Shobara City, Hiroshima-ken 727-0023, Japan
| | | | | | | | | | | |
Collapse
|
42
|
Taguchi H, Keck Z, Foung SKH, Paul S, Nishiyama Y. Antibody light chain-catalyzed hydrolysis of a hepatitis C virus peptide. Bioorg Med Chem Lett 2004; 14:4529-32. [PMID: 15357986 DOI: 10.1016/j.bmcl.2004.06.044] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2004] [Revised: 06/12/2004] [Accepted: 06/12/2004] [Indexed: 10/26/2022]
Abstract
A panel of human monoclonal and recombinant antibody light chains was screened for cleavage of the synthetic peptide corresponding to a neutralizing epitope of hepatitis C virus (residues 192-205 of envelope glycoprotein E1). One of the 39 light chains studied hydrolyzed the Val197-Ser198 bond of the peptide with Km and kcat values of 223 +/- 7 microM and 0.087 +/- 0.001 min(-1).
Collapse
Affiliation(s)
- Hiroaki Taguchi
- Chemical Immunology and Therapeutics Research Center, Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, 6431 Fannin, 77030, USA
| | | | | | | | | |
Collapse
|
43
|
Hifumi E, Kondo H, Mitsuda Y, Uda T. Catalytic features of monoclonal antibody i41SL1-2 subunits. Biotechnol Bioeng 2004; 84:485-93. [PMID: 14574707 DOI: 10.1002/bit.10806] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A monoclonal antibody (mAb), i41SL1-2, was obtained by immunizing the peptide of complementarity-determining region-1 (CDRL-1: RSSKSLLYSNGNTYLY) of a super catalytic antibody light chain, 41S-2-L, capable of enzymatically destroying the gp41 molecule of the HIV-1 envelope. From the DNA and the deduced amino acid sequences of the light and heavy chain of i41SL1-2 mAb, molecular modeling was conducted that suggested that both subunits of i41SL1-2 mAb possess catalytic triads in their structures. Especially the light chain of i41SL1-2 mAb possesses a characteristic catalytic triad composed of Asp(1), Ser(27A), and His(93), whose positions are identical to the catalytic antibody light chain, VIPase, of S. Paul and colleagues (see text). The antibody gene of i41SL1-2 light chain and VIPase belong to the same germline, bd2, suggesting that the discrete germline inherently possesses catalytic activity. Both light and heavy chains of i41SL1-2 mAb degraded the antigenic peptide CDRL-1 within 47 and 57 h, respectively. The catalytic reaction constant (kcat) of the light and heavy chain was 6.1 x 10(-1) and 6.2 x 10(-1) min(-1), respectively. These are high values for the natural catalytic antibodies reported so far. The catalytic efficiency (kcat/Km) of the light and heavy chain was 3.1 x 10(5) and 4.9 x 10(4) M(-1) min(-1), respectively. The first cleaved bond of the antigenic peptide by subunits of i41SL1-2 mAb was between Arg(1) and Ser(2) in the sequence of CDRL-1, suggesting a serine protease character.
Collapse
Affiliation(s)
- Emi Hifumi
- Hiroshima Prefectural University, School of Biosciences, Shobara City, Hiroshima-ken 727-0023, Japan
| | | | | | | |
Collapse
|
44
|
Ohara K, Munakata H, Hifumi E, Uda T, Matsuura K. Improvement of catalytic antibody activity by protease processing. Biochem Biophys Res Commun 2004; 315:612-6. [PMID: 14975745 DOI: 10.1016/j.bbrc.2004.01.094] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2004] [Indexed: 11/16/2022]
Abstract
An immunoglobulin L chain (HIR) was treated with lysyl-endopeptidase. Gel filtration chromatography of the digestion mix identified a peak displaying a significantly higher specific catalytic activity than that of the original sample. The protein in the peak was 11 kDa in size and constituted the VL fragment of HIR. The Km and Kcat values of Chromozym TRY hydrolysis for HIR were 1.5 x 10(-4) M and 6.2 min(-1), and for the VL fragment 7.3 x 10(-4) M and 4.8 x 10(2) min(-1), respectively. Three out of the five BJPs studied in this paper displayed elevated catalytic activity after processing with lysyl-endopeptidase. Similar results were also obtained for the complete antibody.
Collapse
|
45
|
Hatiuchi K, Hifumi E, Mitsuda Y, Uda T. Endopeptidase character of monoclonal antibody i41-7 subunits. Immunol Lett 2003; 86:249-57. [PMID: 12706527 DOI: 10.1016/s0165-2478(03)00030-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
We prepared six anti-idiotypic monoclonal antibodies (mAbs) against parent 41S-2 mAb whose light chain is a super catalytic antibody (41S-2-L) capable of degrading targeted HIV-1gp41 molecule. Out of the obtained six mAbs, i41-7 mAb showed the strongest affinity to the parent 41S-2 mAb. The three dimensional structure of i41-7 mAb was created by molecular modeling using the deduced amino acid sequence of the light and heavy chain of i41-7 mAb. It suggests that the light and heavy chain possess catalytic triad-like structure composed of Ser, His and Asp in their conformations. Both chains of i41-7 mAb could cleave peptide bond of some peptides such as a polypeptide, TP41-1 (TPRGPDRPEGIEEEGGERDRD), as anticipated. The cleaving reaction advanced in accordance with Michaelis-Menten equation. The catalytic efficiency (kcat/Km) of light and heavy chain was 9.1 x 10(3) and 1.7 x 10(4) M(-1) x min(-1), respectively, while the intact i41-7 mAb did not exhibit any catalytic activity. The first cleaved bond of the TP41-1 peptide by the light chain was between 14E and 15G in the sequence. It was revealed that both light and heavy chains had endopeptidase characteristics.
Collapse
MESH Headings
- Animals
- Antibodies, Anti-Idiotypic/biosynthesis
- Antibodies, Anti-Idiotypic/chemistry
- Antibodies, Anti-Idiotypic/isolation & purification
- Antibodies, Catalytic/biosynthesis
- Antibodies, Catalytic/chemistry
- Antibodies, Catalytic/isolation & purification
- Antibodies, Monoclonal/biosynthesis
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/isolation & purification
- Antibody Specificity
- Catalytic Domain/physiology
- Chromatography, High Pressure Liquid
- Endopeptidases
- Enzyme-Linked Immunosorbent Assay
- HIV Envelope Protein gp41/metabolism
- Hybridomas
- Immunoglobulin Heavy Chains/chemistry
- Immunoglobulin Heavy Chains/isolation & purification
- Immunoglobulin Light Chains/chemistry
- Immunoglobulin Light Chains/isolation & purification
- Immunoglobulin Light Chains/metabolism
- Models, Molecular
- Protein Structure, Quaternary
Collapse
Affiliation(s)
- Kenji Hatiuchi
- School of Biosciences, Hiroshima Prefectural University, Shobara City 727-0023, Japan
| | | | | | | |
Collapse
|